Registration Programme Overview Exhibition Virtual Exhibition Satellite Programme Hotel Information VISA Letter Application

 

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparative study of the efficacy and tolerability of common ophthalmic non steroid anti-inflammatory drugs in patients following cataract surgery

Poster Details


First Author: Z.Kapsala GREECE

Co Author(s): D. Pagoulatos   G. Bontzos   I. Georgalas              

Abstract Details

Purpose:

To compare the efficacy and tolerability of ketorolac 0.5%, nepafenac 1mg/ml and bromfenac 0.9mg/ml after uncomplicated cataract surgery.

Setting:

General Hospital of Athens «Ippokratio», Athens, Greece.

Methods:

63 eyes of 63 subjects who underwent uncomplicated phacoemulcification and implantation of foldable intraocular lens were included in this prospective study. Patients were randomly assigned to 1 of 3 treatment groups; treatment included instillation of ketorolac 0.5% (21 eyes), nepafenac 1mg/ml (21 eyes) and bromfenac 0.9mg/ml (21 eyes) ophthalmic solutions three times daily in combination with a topical antibiotic for 30 days beginning the first postoperative day. Following parameters were evaluated: anterior chamber inflammation, intraocular pressure and presence of macular edema. All assessements were performed at week 1, month1 and month 2 after surgery.

Results:

No significant difference was observed regarding anterior chamber inflammation, intraocular pressure and central macular thickness among the different treatment groups at all postoperative visits. Moreover, all treatment groups reported no significant adverse event during the study period except for a transient, mild ocular burning sensation immediately after instillation in the ketorolac group.

Conclusions:

All three NSAIDs controlled equally effectively ocular inflammation and increase of macular thickness after an uncomplicated cataract surgery. They seem to be well tolerated with no significant adverse events noted during the therapy period.

Financial Disclosure:

None

Back to Poster listing